翰宇药业董事长曾少贵在签约仪式上表示："本次系列商业化协议的落地，是双方在减重治疗领域进程 加速的重要里程碑。我们高度认可三生蔓迪在消费属性药物领域强大的品牌影响力和营销网络覆盖实 力。翰宇药业也将充分发挥多肽药物研发与规模化生产的核心优势，确保高质量产品的稳定供应。" 三生制药董事长娄竞指出："三生蔓迪深耕消费医疗市场多年，对中国减重市场的巨大潜力始终保持坚 定信心。双方合作的司美格鲁肽注射液（减重适应症）项目进展令人鼓舞。我们有信心凭借优势互补， 把这款具备国际品质的减重产品快速推向市场，让更多患者第一时间用上具有国际品质保障的国产 GLP-1药物。" 签约当日，双方围绕注册进展、上市筹备时间规划、市场推广策略、销量预期、供应链备货及后续产品 布局等六大方向展开了深入讨论，并达成多项共识。同时，根据协议，供货价将基于非约束性销量预 测，按年采购量≤500万支、500万–1000万支、>1000万支进行分阶段成本测算与梯度报价，预计年销售 峰值3000万支（实际以商业批订单为准）。 研发端显示，双方合作项目司美格鲁肽（减重）由北京大学人民医院纪立农教授担任主要研究者的多中 心、随机、开放、平行、阳性对照Ⅲ期 ...

Market Overview - On August 19, the Hang Seng Index fell by 0.21%, closing at 25,122.90 points, while southbound funds through the Stock Connect recorded a net inflow of HKD 18.573 billion [1][3] - The total trading volume for the Stock Connect on August 19 was HKD 168.997 billion, with a net buy of HKD 18.573 billion [1][3] Trading Activity - In the Shanghai Stock Connect, the trading volume was HKD 103.202 billion, with a net buy of HKD 8.911 billion; in the Shenzhen Stock Connect, the trading volume was HKD 65.795 billion, with a net buy of HKD 9.662 billion [1][3] - The most actively traded stock in the Shanghai Stock Connect was Dongfang Zhenxuan, with a trading volume of HKD 7.043 billion, followed by the Tracker Fund of Hong Kong and Tencent Holdings, with trading volumes of HKD 5.106 billion and HKD 3.221 billion, respectively [1][2] Net Buy and Sell Analysis - The Tracker Fund of Hong Kong had the highest net buy amount of HKD 5.089 billion, despite a closing price drop of 0.16% [1][2] - The stock with the highest net sell amount was Hua Hong Semiconductor, with a net sell of HKD 149 million and a closing price drop of 3.12% [1][2] Shenzhen Stock Connect Highlights - In the Shenzhen Stock Connect, Dongfang Zhenxuan also led in trading volume with HKD 3.294 billion, followed by Hang Seng China Enterprises and the Tracker Fund of Hong Kong, with trading volumes of HKD 2.215 billion and HKD 2.021 billion, respectively [2] - The stock with the highest net buy in the Shenzhen Stock Connect was Hang Seng China Enterprises, with a net buy of HKD 2.215 billion, despite a closing price drop of 0.37% [2]

Core Insights - The explosive growth of BD transactions in China's innovative pharmaceutical industry signifies a phase of industrial upgrading, but underlying issues must be addressed [1][2]. BD Transaction Growth - In 2024, China's total pharmaceutical BD transaction volume reached $63.5 billion, a year-on-year increase of 22.59%, with 24 major transactions exceeding $500 million, totaling $43 billion, accounting for nearly 20% of global major transactions [2]. - The growth momentum is expected to strengthen in 2025, with a 42% share of global transactions exceeding $50 million in the first five months, a significant increase from 5% in 2021 [2]. - Notable transactions include the licensing of SSGJ-707 by 3SBio to Pfizer for a $1.25 billion upfront payment and a total value exceeding $6 billion, and the agreement between Hengrui Medicine and GSK for HRS-9821 with a $500 million upfront payment and a potential total of $12.5 billion [2]. Challenges in BD Transactions - The current BD transactions primarily involve innovative pharmaceutical companies licensing early-stage assets to multinational firms for global development, which is crucial for cash flow and global recognition [3]. - However, the focus on clinical-stage BD transactions poses long-term challenges, as a significant reduction in preclinical pipelines may hinder subsequent R&D and commercialization capabilities [3]. - In 2024, over 15 domestic pharmaceutical companies, including East China Pharmaceutical and BeiGene, announced project terminations, with Shanghai Pharmaceuticals terminating 12 new drug pipelines within a year, resulting in losses of nearly $700 million [3]. Structural Issues in the Industry - The transition from generic to original research drugs reveals deep-seated challenges, as companies are forced to "sell seedlings" (potential pipelines) for survival, undermining the ability to cultivate "big fish" (blockbuster innovations) [4]. - Many clinical-stage innovative pharmaceutical companies face dual pressures: weak self-financing capabilities and shrinking external financing channels, leading to acceptance of low-premium BD transactions [4]. - The imbalance in negotiation power between resource-rich multinational firms and local companies in clinical research stages exacerbates the situation, limiting the long-term value for local firms [4]. Case Study: Pumis Bio - Pumis Bio licensed its bispecific antibody product BNT-327 for an upfront payment of $55 million, but when BioNTech resold the rights to BMS, the valuation soared to $11.1 billion, illustrating a significant value gap where the original developer received less than 0.5% of the final value [5]. - Such transactions, while addressing immediate financial needs, often sacrifice long-term value and contribute to the loss of strategic innovative assets [5]. Production and Talent Challenges - The demand for key production processes related to innovative drugs is shifting overseas, leading to stagnation in the capabilities of local CDMO firms, which affects the resilience of the domestic supply chain [6]. - The shift in risk capital focus from early-stage high-risk original innovations to lower-risk later-stage projects exacerbates the talent drain in foundational research, further deteriorating the innovation ecosystem [6]. Industry Value Chain Concerns - The integrity of the industry value chain is under threat, with local firms at risk of becoming concentrated in the "OEM segment," leading to a decrease in industry added value and hindering sustainable high-quality development [7]. - The increasing share of imported innovative drugs in healthcare spending is squeezing the payment space for local original research drugs [7]. Recommendations for Sustainable Development - To address the structural contradictions behind the short-term prosperity of BD transactions, a sustainable innovation ecosystem must be established, promoting a positive cycle among R&D, capital, market, and payment [8]. - Key strategies include deepening pricing and payment reforms, broadening financing channels, improving clinical application support policies, standardizing clinical promotion, and enhancing national strategic participation in major original research projects [8][9][10].

Core Insights - On August 19, 2025, Oriental Selection (01797), Tracker Fund of Hong Kong (02800), and Tencent Holdings (00700) were the top three stocks by trading volume in the Southbound Stock Connect, with trading amounts of 7.043 billion, 5.106 billion, and 3.221 billion respectively [1] - In the Shenzhen-Hong Kong Stock Connect, Oriental Selection (01797), Hang Seng China Enterprises Index ETF (02828), and Tracker Fund of Hong Kong (02800) were the top three stocks, with trading amounts of 3.294 billion, 2.215 billion, and 2.021 billion respectively [1] Southbound Stock Connect - Top Active Companies - Oriental Selection (01797) had a trading amount of 7.043 billion with a net buy of -48.8231 million [2] - Tracker Fund of Hong Kong (02800) recorded a trading amount of 5.106 billion with a net buy of 5.089 billion [2] - Tencent Holdings (00700) had a trading amount of 3.221 billion with a net buy of 979 million [2] - Alibaba Group (09988) had a trading amount of 2.547 billion with a net buy of -7.2321 million [2] - SMIC (00981) recorded a trading amount of 2.084 billion with a net buy of 160.3 million [2] Shenzhen-Hong Kong Stock Connect - Top Active Companies - Oriental Selection (01797) had a trading amount of 3.294 billion with a net buy of -464 million [2] - Hang Seng China Enterprises Index ETF (02828) recorded a trading amount of 2.215 billion with a net buy of 2.215 billion [2] - Tracker Fund of Hong Kong (02800) had a trading amount of 2.021 billion with a net buy of 1.982 billion [2] - Tencent Holdings (00700) recorded a trading amount of 2.018 billion with a net buy of 46.322 million [2] - Alibaba Group (09988) had a trading amount of 1.984 billion with a net buy of 268 million [2]

免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 南向资金成交活跃个股榜单中，净买入个股共7只，金额最多的是腾讯控股（0700.HK，收盘价：592.5 港元），净买入10.256亿港元；净卖出个股共4只，金额最多的是东方甄选（1797.HK，收盘价：34.32 港元），净卖出5.126亿港元。 | 南向资金今日成交活跃个股榜单 | | --- | | 代理 | 简称 | 收盘价 (港元) | 准铁帽 (%) | 净买入金额 (亿港元) | | | --- | --- | --- | --- | --- | --- | | 0700.HK | 腾讯控股 | 592.5 | 0.94 | 10.26 | = | | 1810.HK | 小米集团-W | 52.4 | -1.23 | 7.39 | . | | 1530.HK | 三生制药 | 31.54 | -3.01 | 2.82 | = | | 9988.HK | 阿里巴巴-W | 118.3 | -0.25 | 2.60 | | | 2228.HK | 晶泰控股 | 8.74 | -2.89 | 1.79 | | | 3 ...

Summary of Key Points Core Viewpoint - The Hong Kong stock market saw significant net inflows from Northbound trading, with a total net buy of HKD 185.73 billion on August 19, 2023, indicating strong investor interest in Hong Kong stocks [1]. Northbound Trading Activity - Northbound trading through Stock Connect recorded a net buy of HKD 89.11 billion from Shanghai and HKD 96.62 billion from Shenzhen [1]. - The most bought stocks included the Tracker Fund of Hong Kong (02800), Hang Seng China Enterprises (02828), and Southern Hang Seng Technology (03033) [1]. - The most sold stocks were Oriental Selection (01797), SMIC (00981), and Hua Hong Semiconductor (01347) [1]. Individual Stock Performance - **Tracker Fund of Hong Kong (02800)**: Net buy of HKD 70.7 billion [6]. - **Hang Seng China Enterprises (02828)**: Net buy of HKD 22.14 billion [6]. - **Southern Hang Seng Technology (03033)**: Net buy of HKD 14.11 billion [6]. - **Tencent Holdings (00700)**: Net buy of HKD 10.25 billion; reported a 15% year-on-year revenue growth to HKD 184.5 billion and a 17% increase in net profit [6]. - **Xiaomi Group (01810)**: Net buy of HKD 7.39 billion; reported a 30% year-on-year revenue increase to HKD 115.96 billion [7]. - **Sangfor Technologies (01530)**: Net buy of HKD 2.82 billion; recently completed a share placement to Pfizer [7]. - **Jingtao Holdings (02228)**: Net buy of HKD 1.79 billion; expects a significant increase in revenue and profit for the first half of 2025 [8]. Market Sentiment and Future Outlook - Analysts from Industrial Securities maintain a bullish outlook on Hong Kong stocks, predicting a long-term bull market driven by increasing confidence among global and Chinese investors [6]. - The potential for a Federal Reserve interest rate cut is seen as a catalyst for further liquidity in the Hong Kong market [6].

格隆汇8月19日丨三生制药(01530.HK)宣布，本公司将于2025年8月29日（星期五）举行董事会会议，藉 以（其中包括）审议及批准刊发本公司及其附属公司截至2025年6月30日止六个月的未经审核中期业绩 及其发布，并考虑派发中期股息（如有）。 ...

三生制药（「本公司」）董事會（「董事會」）謹 此 宣 佈，本 公 司 將 於 二 零 二 五 年 八 月 二十九日（星 期 五）舉 行 董 事 會 會 議，藉 以（其 中 包 括）審議及批准刊發本公司及其 附 屬 公 司 截 至 二 零 二 五 年 六 月 三 十 日 止 六 個 月 之 未 經 審 核 中 期 業 績 及 其 發 佈， 並考慮派發中期股息（如 有）。 承董事會命 三生制药 主 席 婁競博士 香 港，二 零 二 五 年 八 月 十 九 日 於 本 公 告 日 期，董 事 會 包 括 執 行 董 事 婁 競 博 士 及 蘇 冬 梅 女 士；非 執 行 董 事 張 皎 娥 女 士；以 及 獨 立 非 執 行 董 事 濮 天 若 先 生、楊 凱 蒂 女 士 及 黃 祖 耀 先 生。 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 的 全 部 或 任 何 部 份 內 容 而 產 生 或 因 依 賴 ...

Core Viewpoint - The Hong Kong stock market for innovative drugs experienced a notable pullback, with the Hong Kong Innovative Drug ETF (520880) declining by 2.6% on August 19, despite a positive sentiment indicated by a real-time premium rate of 0.28% [1][3]. Group 1: Company Performance - China National Pharmaceutical Group reported a revenue of 17.57 billion yuan and a net profit of 3.39 billion yuan for the first half of the year, reflecting year-on-year growth of 10.7% and 140.2% respectively, marking three consecutive reporting periods of double-digit stable growth [3]. - The strong performance of China National Pharmaceutical Group was attributed to better-than-expected revenue growth from innovative products and dividend income [3]. Group 2: Market Trends - As of August 18, the Hong Kong Innovative Drug ETF (520880) tracked the Hang Seng Hong Kong Innovative Drug Selected Index, which has seen a year-to-date increase of 112.33%, significantly outperforming the Hang Seng Index (23.50%) and the Hang Seng Technology Index (22.05%) by 86.82 and 87.46 percentage points respectively [3]. - The adjustment in the market is viewed as a technical correction following a rapid increase, with long-term support expected from domestic policy and overseas value recognition for Chinese innovative drugs [3][6]. Group 3: Industry Outlook - The innovative drug industry is anticipated to undergo a value reassessment, supported by national policy and a clear trend of industry development and upgrading [5][6]. - The innovative drug sector is entering a 2.0 era, with domestic products gradually transitioning from following to leading innovation, benefiting from a favorable environment including engineer advantages, rich clinical resources, and supportive policies [6]. - The Hong Kong Innovative Drug ETF (520880) is the first ETF to passively track the Hang Seng Hong Kong Innovative Drug Selected Index, focusing on the innovative drug industry chain with a high concentration of leading stocks [6].

Group 1 - The core viewpoint of the news is that Hong Kong's innovative pharmaceutical stocks experienced a decline, with notable drops in companies such as China Biologic Products, which fell over 7%, and others like Innovent Biologics, WuXi Biologics, and 3SBio, which dropped over 4% [1] - Several Hong Kong innovative pharmaceutical ETFs also saw a decline of approximately 3% due to market influences [1] Group 2 - Specific ETF performance includes: - Hong Kong Innovative Pharmaceutical ETF Fund (520700) at 1.859, down 3.03% - Hong Kong Innovative Pharmaceutical 50 ETF (513780) at 1.920, down 2.98% - Hong Kong Innovative Pharmaceutical ETF (520880) at 1.272, down 2.90% - Other ETFs also reported declines ranging from 2.55% to 2.98% [2] - Analysts noted that multinational pharmaceutical companies have significantly increased their procurement of innovative drug patents in China this year, with procurement amounts from January to May nearing the total expected for 2024, indicating the competitiveness of China's innovative drugs in the international market [2]